Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc's Soliris (eculizumab) Receives Positive Opinion From Committee For Orphan Medicinal Products For Treatment Of Neuromyelitis Optica


Tuesday, 16 Jul 2013 06:32am EDT 

Alexion Pharmaceuticals Inc announced that Soliris (eculizumab), the Company's terminal complement inhibitor, has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder. The positive opinion of the COMP has been forwarded to the European Commission for final approval and publication in the community register. 

Company Quote

162.89
-1.63 -0.99%
10 Jul 2014